NYSE:TAK

Takeda Pharmaceutical - TAK Stock Forecast, Price & News

$14.56

0.00 (0.00%)

(As of 12/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $14.43
▼
$14.64
50-Day Range: $12.42
▼
$14.87
52-Week Range: $12.28
▼
$15.36

Volume: 2.37 million shs
Average Volume: 2.76 million shs
Market Capitalization: $45.15 billion

P/E Ratio: 26.96
Dividend Yield: 3.71%
Price Target: $24.00

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 64.8% Upside
$24.00 Price Target
Short Interest: Healthy
0.18% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.77
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

167th out of 1,023 stocks

Pharmaceutical Preparations Industry

61st out of 501 stocks

3.3

Analyst's Opinion

Consensus Rating
Takeda Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.00, Takeda Pharmaceutical has a forecasted upside of 64.8% from its current price of $14.56.
Amount of Analyst Coverage
Takeda Pharmaceutical has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.18% of the float of Takeda Pharmaceutical has been sold short.
Short Interest Ratio / Days to Cover
Takeda Pharmaceutical has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Takeda Pharmaceutical has recently increased by 39.10%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Leadership
Takeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 3.71%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Takeda Pharmaceutical does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Takeda Pharmaceutical is 100.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TAK.

2.7

News and Social Media Coverage

News Sentiment
Takeda Pharmaceutical has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Takeda Pharmaceutical this week, compared to 3 articles on an average week.
Search Interest
Only 10 people have searched for TAK on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Takeda Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.
Percentage Held by Institutions
Only 1.96% of the stock of Takeda Pharmaceutical is held by institutions.

3.1

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Takeda Pharmaceutical is 26.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.92.
Price to Earnings Ratio vs. Sector
The P/E ratio of Takeda Pharmaceutical is 26.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.73.
Price to Earnings Growth Ratio
Takeda Pharmaceutical has a PEG Ratio of 0.65. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Takeda Pharmaceutical has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

December 6, 2022 | marketwatch.com

Consumer Healthcare Market Players to drive Merges and Acquisition Strategies to Expand Market Share, 2023-2025

December 5, 2022 | marketwatch.com

Teduglutide Market Size 2023 Observe Exponential Growth, Facts and Figures with Condensed Reports, and Forecast till 2029

December 2, 2022 | finance.yahoo.com

Global Blood Plasma Derivatives Market Report 2022: Featuring Bayer, Takeda Pharmaceutical, Grifols, Biotest & More

November 30, 2022 | finance.yahoo.com

Japan’s Government Stayed Out of Currency Markets in November

November 27, 2022 | marketwatch.com

Actovegin Market Dynamics with Top Players, Gross Margin, Regional Demand, Plans and Demand Status Forecast to 2028

November 26, 2022 | marketwatch.com

Insomnia Medication Market 2022 : Projected to Deliver Greater Revenues during the Forecast Period 2028

November 25, 2022 | marketwatch.com

Ewing Sarcoma Drugs Market : Analysis by Size, Share Trends, Future Growth, Emerging Trends, Qualitative Outlook and Global Forecast to 2028

November 22, 2022 | finance.yahoo.com

Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

November 18, 2022 | uk.finance.yahoo.com

Lyophilization in pharmaceuticals market is projected to grow at a CAGR of 13.0% by 2033: Visiongain Reports Ltd

November 17, 2022 | finance.yahoo.com

Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US

November 11, 2022 | marketwatch.com

What's Driving the Amyotrophic Lateral Sclerosis Treatment Market Growth 2022-2026?

November 11, 2022 | finance.yahoo.com

European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies

November 9, 2022 | marketwatch.com

Eptifibatide Injection Market Trends 2023 Growth Factor, Industry Challenge, Share, Business Overview, Size and Forecast to 2028

November 8, 2022 | finance.yahoo.com

THE CANADIAN INFLAMMATORY BOWEL DISEASE RESEARCH CONSORTIUM AWARDS FIRST $1M PIONEER GRANT FROM TAKEDA CANADA

November 4, 2022 | benzinga.com

Next Generation Antibody Therapeutics Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | DataM Intelligence

October 27, 2022 | marketwatch.com

Takeda Pharmaceutical 2Q Net Profit Y61.74B, Given Y105.01B Net Profit in 1Q, WSJ Calculation Shows

October 27, 2022 | markets.businessinsider.com

Takeda H1 Profit Down, Revenues Rise; Lifts FY22 Outlook - Quick Facts

October 27, 2022 | marketwatch.com

Takeda Pharmaceutical Second-Quarter Net Profit Missed Analysts' Expectations -- Earnings Review

October 26, 2022 | benzinga.com

Global Diabetes Therapeutics Market Report to 2030 - Featuring Novartis, Novo Nordisk, Sanofi and Takeda Pharmaceutical Among Others

October 20, 2022 | finance.yahoo.com

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

October 16, 2022 | markets.businessinsider.com

Takeda: CHMP Recommends Approval Of Dengue Vaccine Candidate, TAK-003

October 15, 2022 | msn.com

EU regulator recommends clearing Takeda’s dengue vaccine

October 14, 2022 | reuters.com

EU regulator backs Takeda's dengue vaccine

October 14, 2022 | washingtonpost.com

EU regulator recommends clearing Takeda's dengue vaccine

October 14, 2022 | finance.yahoo.com

Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Company Calendar

Last Earnings: 10/27/2022
Today: 12/06/2022
Next Earnings (Estimated): 2/02/2023
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:TAK
CUSIP: N/A
CIK: 1395064
Web: www.takeda.com
Phone: (166) 204-2111
Fax: 813-3278-2268
Employees: 47,347
Year Founded: 1781

Price Target and Rating

Average Stock Price Forecast: $24.00
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +64.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.54
Trailing P/E Ratio: 26.96
Forward P/E Ratio: 6.93
P/E Growth: 0.65
Net Income: $2.05 billion
Net Margins: 5.60%
Pretax Margin: 5.86%
Return on Equity: 12.76%
Return on Assets: 5.61%

Debt

Debt-to-Equity Ratio: 0.62
Current Ratio: 1.15
Quick Ratio: 0.75

Sales & Book Value

Annual Sales: $31.79 billion
Price / Sales: 1.42
Cash Flow: $3.52 per share
Price / Cash Flow: 4.14
Book Value: $16.31 per share
Price / Book: 0.89

Miscellaneous

Outstanding Shares: 3,100,722,000
Free Float: 3,099,482,000
Market Cap: $45.15 billion
Optionable: Optionable
Beta: 0.69

Social Links

Key Executives

Mr. Christophe Weber (Age 56)
Pres, CEO & Representative Director
Comp: $4.02M

Mr. Constantine Saroukos (Age 51)
CFO & Representative Director
Comp: $2.4M

Dr. Andrew S. Plump (Age 57)
Pres of R&D and Representative Director
Comp: $2.28M

Dr. Seigo Izumo
Chair of Management Board

Mr. Haruhiko Hirate (Age 65)
Member of Management Board

Salvatore Alesci
Member of Management Board and Head of R&D Global Science & Biomedical Policy

Norimasa Takeda
Chief Accounting Officer & Corp. Controller

Mr. Iwaaki Taniguchi
Sr. VP of Corp. Fin. & Controlling Department

Mr. Gabriele Ricci (Age 44)
Chief Data & Technology Officer

Mr. Christopher David O'Reilly
Global Head of Investor Relations & Global Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.
What is Takeda Pharmaceutical's stock price forecast for 2023?: 4 brokers have issued 12 month target prices for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $24.00 to $24.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 64.8% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.
How have TAK shares performed in 2022?: Takeda Pharmaceutical's stock was trading at $13.63 at the start of the year. Since then, TAK shares have increased by 6.8% and is now trading at $14.56.
View the best growth stocks for 2022 here.
Are investors shorting Takeda Pharmaceutical?: Takeda Pharmaceutical saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,550,000 shares, an increase of 39.1% from the October 31st total of 3,990,000 shares. Based on an average daily volume of 3,020,000 shares, the short-interest ratio is presently 1.8 days. Approximately 0.2% of the company's shares are short sold.
View Takeda Pharmaceutical's Short Interest.
When is Takeda Pharmaceutical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our TAK earnings forecast.
How were Takeda Pharmaceutical's earnings last quarter?: Takeda Pharmaceutical Company Limited (NYSE:TAK) issued its quarterly earnings results on Thursday, October, 27th. The company reported $0.52 earnings per share (EPS) for the quarter. The business earned $7.26 billion during the quarter. Takeda Pharmaceutical had a net margin of 5.60% and a trailing twelve-month return on equity of 12.76%.
Is Takeda Pharmaceutical a good dividend stock?: Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.54 per share and currently has a dividend yield of 3.71%. The dividend payout ratio is 100.00%. Payout ratios above 75% are not desirable because they may not be sustainable.
What guidance has Takeda Pharmaceutical issued on next quarter's earnings?: Takeda Pharmaceutical issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of $3.80-$3.80 for the period. The company issued revenue guidance of $28.46 billion-$28.46 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).
What is Takeda Pharmaceutical's stock symbol?: Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."
Who are Takeda Pharmaceutical's major shareholders?: Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (0.13%), Renaissance Technologies LLC (0.09%), BlackRock Inc. (0.07%), Brandes Investment Partners LP (0.06%), Van ECK Associates Corp (0.06%) and Barclays PLC (0.05%).
How do I buy shares of Takeda Pharmaceutical?: Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Takeda Pharmaceutical's stock price today?: One share of TAK stock can currently be purchased for approximately $14.56.
How much money does Takeda Pharmaceutical make?: Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $45.15 billion and generates $31.79 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.54 on an earnings per share basis.
How many employees does Takeda Pharmaceutical have?: The company employs 47,347 workers across the globe.
Does Takeda Pharmaceutical have any subsidiaries?: The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?: Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial